Latest Ratios: P/E Ratio 16.0x · EV/EBITDA 10.8x · ROE 11.8%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $501M | $745M | $825M | $839M | $949M | $1.0B | $1.2B | $1.7B | $2.7B | $4.8B | $5.3B |
| Enterprise Value | $685M | $929M | $986M | $1.0B | $1.2B | $1.3B | $1.5B | $2.1B | $2.9B | $5.1B | $5.5B |
| P/E Ratio → | 16.01 | 23.57 | 26.23 | 22.94 | 48.26 | 53.12 | — | 17.94 | 33.33 | 58.27 | 82.79 |
| P/S Ratio | 0.95 | 1.42 | 1.58 | 1.65 | 1.94 | 2.22 | 2.45 | 2.52 | 3.79 | 7.35 | 8.91 |
| P/B Ratio | 1.81 | 2.66 | 3.20 | 3.65 | 5.02 | 6.47 | 15.78 | 9.23 | 16.08 | 31.77 | 33.28 |
| P/FCF | 22.20 | 33.00 | 19.04 | 59.06 | 64.38 | 45.21 | 25.93 | 25.01 | 29.45 | 45.96 | 44.10 |
| P/OCF | 13.49 | 20.05 | 14.64 | 33.86 | 38.02 | 28.48 | 20.60 | 18.79 | 23.73 | 39.02 | 40.19 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.76 | 1.88 | 2.04 | 2.36 | 2.71 | 3.09 | 3.07 | 4.18 | 7.67 | 9.25 |
| EV / EBITDA | 10.79 | 14.63 | 13.42 | 14.76 | 19.70 | 19.98 | — | 17.21 | 20.68 | 36.96 | 48.67 |
| EV / EBIT | 14.02 | 19.01 | 16.85 | 19.02 | 27.84 | 28.15 | 30.33 | 20.12 | 24.70 | 46.03 | 62.91 |
| EV / FCF | — | 41.12 | 22.75 | 73.15 | 78.42 | 55.30 | 32.74 | 30.52 | 32.52 | 47.98 | 45.78 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.9% | 17.9% | 16.9% | 18.4% | 16.1% | 17.8% | 21.0% | 25.8% | 25.8% | 24.3% | 21.1% |
| Operating Margin | 9.3% | 9.3% | 11.2% | 10.7% | 8.5% | 9.6% | -15.8% | 14.5% | 16.9% | 17.0% | 14.5% |
| Net Profit Margin | 6.0% | 6.0% | 6.0% | 7.2% | 4.0% | 4.2% | -20.0% | 15.3% | 11.3% | 12.6% | 10.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.8% | 11.8% | 12.9% | 17.5% | 11.1% | 16.7% | -75.8% | 58.7% | 50.1% | 53.3% | 90.7% |
| ROA | 5.4% | 5.4% | 5.3% | 6.3% | 3.4% | 3.4% | -14.5% | 14.3% | 12.9% | 14.4% | 10.7% |
| ROIC | 8.3% | 8.3% | 10.3% | 9.9% | 7.9% | 8.7% | -12.2% | 14.6% | 22.1% | 23.2% | 17.2% |
| ROCE | 9.9% | 9.9% | 11.8% | 11.2% | 8.6% | 9.3% | -13.5% | 16.0% | 23.1% | 23.7% | 17.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.74 | 0.74 | 0.70 | 0.94 | 1.18 | 1.55 | 4.33 | 2.10 | 1.76 | 1.49 | 1.36 |
| Debt / EBITDA | 3.25 | 3.25 | 2.45 | 3.06 | 3.79 | 3.92 | — | 3.20 | 2.04 | 1.66 | 1.91 |
| Net Debt / Equity | — | 0.66 | 0.62 | 0.87 | 1.10 | 1.44 | 4.14 | 2.04 | 1.68 | 1.39 | 1.27 |
| Net Debt / EBITDA | 2.89 | 2.89 | 2.19 | 2.84 | 3.53 | 3.65 | — | 3.11 | 1.95 | 1.55 | 1.78 |
| Debt / FCF | — | 8.12 | 3.71 | 14.09 | 14.04 | 10.09 | 6.81 | 5.51 | 3.07 | 2.02 | 1.68 |
| Interest Coverage | 4.95 | 4.95 | 4.73 | 4.07 | 3.59 | 4.95 | 3.45 | 6.94 | 8.90 | 10.24 | 7.56 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.07 | 2.07 | 2.32 | 2.53 | 2.05 | 2.08 | 1.85 | 1.98 | 2.25 | 1.98 | 1.79 |
| Quick Ratio | 1.57 | 1.57 | 1.71 | 1.72 | 1.47 | 1.58 | 1.42 | 1.53 | 1.81 | 1.66 | 1.47 |
| Cash Ratio | 0.21 | 0.21 | 0.20 | 0.17 | 0.15 | 0.20 | 0.15 | 0.10 | 0.13 | 0.14 | 0.14 |
| Asset Turnover | — | 0.88 | 0.89 | 0.87 | 0.85 | 0.81 | 0.86 | 0.86 | 1.08 | 1.13 | 1.04 |
| Inventory Turnover | 7.93 | 7.93 | 7.33 | 5.80 | 6.80 | 8.50 | 10.10 | 9.88 | 11.39 | 14.98 | 13.92 |
| Days Sales Outstanding | — | 78.70 | 88.74 | 88.11 | 85.79 | 82.85 | 62.32 | 75.44 | 67.26 | 73.63 | 70.17 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 1.0% | 5.8% | 3.7% | 2.0% | 1.8% |
| Payout Ratio | 5.9% | 5.9% | 6.0% | 5.1% | 9.5% | 9.3% | — | 95.7% | 122.3% | 116.9% | 148.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.2% | 4.2% | 3.8% | 4.4% | 2.1% | 1.9% | — | 5.6% | 3.0% | 1.7% | 1.2% |
| FCF Yield | 4.5% | 3.0% | 5.3% | 1.7% | 1.6% | 2.2% | 3.9% | 4.0% | 3.4% | 2.2% | 2.3% |
| Buyback Yield | 2.5% | 1.7% | 0.6% | 0.3% | 0.4% | 0.8% | 0.2% | 0.2% | 0.3% | 0.3% | 0.1% |
| Total Shareholder Yield | 2.8% | 1.9% | 0.9% | 0.5% | 0.6% | 1.0% | 1.3% | 6.0% | 3.9% | 2.4% | 1.9% |
| Shares Outstanding | — | $47M | $48M | $48M | $47M | $47M | $45M | $45M | $44M | $44M | $44M |
Cyclical Revenue Volatility
Based on reported figures, Core Laboratories trades at a TTM P/E of 16.21, which appears to price in a recovery that remains elusive given the company's recent net losses and the broader oilfield services sector's historical tendency to trade at lower multiples during periods of cyclical instability.
The forward P/E of 18.40 suggests that market participants are anticipating a significant rebound in profitability, yet this valuation premium relative to more commoditized peers may be difficult to justify if margin expansion remains constrained by labor inflation. Investors should monitor whether the current valuation reflects a genuine growth trajectory or merely a mispricing of the company's long-term earnings power.
As reported in financial statements, Core Laboratories' ROIC has trended downward to 0.4% in 2026Q1, a significant decline from historical levels that suggests the company is struggling to generate returns above its cost of capital in the current, more challenging international offshore environment.
The decay in ROIC appears driven by the inability to maintain operating margins, which have been compressed by the high fixed-cost nature of the firm's specialized laboratory network. This trend warrants further investigation into whether the company's core petrophysical services are losing their pricing power or if the current capital base is simply too large for the prevailing demand environment.
According to recent quarterly data, the cash conversion cycle has expanded to 97 days in 2026Q1, reflecting a deterioration in working capital efficiency that suggests the company is facing increased difficulty in collecting receivables or managing its inventory levels relative to its own historical performance.
The increase in DSO to 82 days indicates that the company may be granting more lenient payment terms to clients, potentially as a competitive response to maintain market share in a soft demand environment. This lengthening of the cash conversion cycle effectively ties up liquidity, further limiting the firm's ability to self-fund operations during cyclical troughs.
Based on the provided balance sheet data, Core Laboratories has successfully reduced its debt-to-equity ratio to 0.15 as of 2026Q1, a marked improvement that suggests a conservative approach to capital structure management despite the ongoing volatility in the firm's underlying operational cash flows.
While the reduction in debt provides a necessary buffer against sector-specific downturns, the low interest coverage ratio of 0.65 in the most recent quarter indicates that debt service remains a concern if operating income does not recover. Investors should view this deleveraging as a defensive necessity rather than a sign of financial strength, given the current fragility of the bottom line.
The most commonly misapplied metric for Core Laboratories is the asset-light label, which obscures the reality that the company's reliance on highly specialized human capital creates a fixed-cost burden that behaves similarly to heavy industrial assets during periods of revenue contraction.
Investors frequently use low capital expenditure ratios to justify a premium valuation, failing to account for the fact that the firm cannot easily scale down its laboratory staff without destroying its core competitive advantage. A more accurate assessment would involve adjusting for the high fixed-cost nature of its technical labor force rather than relying on traditional asset-light valuation multiples.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLB stock.
Core Laboratories N.V.'s current P/E ratio is 16.0x. The historical average is 33.7x. This places it at the 4th percentile of its historical range.
Core Laboratories N.V.'s current EV/EBITDA is 10.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.6x.
Core Laboratories N.V.'s return on equity (ROE) is 11.8%. The historical average is 53.2%.
Based on historical data, Core Laboratories N.V. is trading at a P/E of 16.0x. This is at the 4th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Core Laboratories N.V.'s current dividend yield is 0.37% with a payout ratio of 5.9%.
Core Laboratories N.V. has 17.9% gross margin and 9.3% operating margin.
Core Laboratories N.V.'s Debt/EBITDA ratio is 3.2x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.